The alliance with Medable enables Covance to expand its decentralised clinical trials technology ecosystem. Credit: National Cancer Institute on Unsplash

US-based life sciences firm LabCorp has announced that Covance, its drug development business, is bolstering its technology ecosystem to speed up the adoption of decentralised clinical trials.

Through an alliance with software provider for digital clinical trials Medable, Covance is expanding its decentralised clinical trials technology ecosystem.

The Covance patient and site interface will be powered by Medable’s modular software platform. This will offer immediate access to applications, which will enable patients to take part in decentralised clinical trials.

Furthermore, the platform will allow data and system interoperability, aid in remote data collection and engagement between sites, patients, and clinical investigators.

Covance Enterprise Solutions president Bill Hanlon said: “Working together, we can apply the full capabilities of LabCorp Diagnostics business, Covance, and our technology ecosystem to extend patient access, improve the patient experience, and accelerate timelines for clinical development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will continue to play a critical role as aggregators and integrators to provide customers with the access, flexibility, and scale necessary to enable global decentralised studies, and to rapidly innovate in ways that improve the patient experience and trial efficiency.”

According to Medable, the firms are creating the first data-driven, decentralised trial ecosystem with this partnership.

Medable co-founder and CEO Michelle Longmire said: “Working with LabCorp Diagnostics and Covance allows us to deepen patient engagement and reduce burden for trial participants, and this decentralised trial ecosystem will help us get effective therapies to patients faster. This innovative ecosystem will accelerate trial timelines.”

Last year, Covance launched a solution to transform the conduct of decentralised clinical trials.